NeuroAiDTM (MLC601, MLC901): A New Bench-to-Bedside Approach to the Treatment of Ischemic Brain Injury

Background and Aim: Faced with the public health burden of stroke and brain damage, various synthetic drugs with different pharmacological targets have been investigated in an attempt to improve clinical outcome, but many failed in clinical trials. In this article, we aimed to outline the current knowledge on the main clinical and pharmacological data of NeuroAiDTM (MLC601, MLC901), a novel product combining extracts from natural sources, in improving neurological and functional recovery after a stroke.

Methods: We reviewed and summarized important findings reported in pre-clinical and clinical publications that investigated the role of NeuroAiDTM in stroke.

Summary of Review: NeuroAiDTM has shown significant pharmacological properties for neuroprotection and neurorestoration in preclinical studies involving animal and cellular models of focal and global ischemia. Clinical studies have shown safety and efficacy data for enhancing neurorecovery beyond acute neuroprotection by reducing long-term neurological deficits and improving functional outcome in post-stroke patients.

Conclusion: NeuroAiDTM offers a safe therapeutic solution likely through a multi-modal mode of action in reducing the burden of ischemic brain injury.